

HIV Prevention Research: Where and How for Communities

Edd Lee

Edd@avac.org

212-367-1534

DAIDS Research Priorities

1. Vaccine Research and Development
2. Translational Research/Drug Development
3. Optimization of Clinical Management,
Including Co-Morbidities
4. Microbicides
5. Prevention of Mother-to-Child Transmission
of HIV
6. Prevention of HIV Infection

US government sponsored HIV prevention research is in a time of flux

DAIDS, NIAID is currently engaged in reorganizing its HIV/AIDS research networks

1. Develop a consortium of linked trial networks
2. Establish priorities across a broad range of clinical research activities
3. Coordinate activities across a broad range of clinical research activities
4. Increase efficiency through resource sharing
5. Flexibly allocate and distribute resources in response to priority research opportunities
6. Leverage complementary strengths and resources within and outside the networks

Source: <http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-05-001.html>

“Old” DAIDS Networks


1. AIEDRP (Acute Infection/Early Disease Research Program)
2. AACTG (Adult AIDS-Clinical Trials Group)
3. ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial)
4. **HPTN** (HIV Prevention Trials Network)
5. **HVTN** (HIV Vaccine Trials Network)
6. **PACTG** (Pediatric AIDS Clinical Trials Group)
7. **CPCRA** (Terry Bein Community Programs for Clinical Research on AIDS)

Bold = Prevention Research

HPTN Research Site Locations



HVTN Trial Sites



STEP Study Merck Sites




New DAIDS Research Networks

1. ACTG (AIDS Clinical Trials Group)
2. **HPTN** (HIV Prevention Trials Network)
3. **HVTN** (HIV Vaccine Trials Network)
4. INSIGHT (International Network for Strategic Initiatives in Global HIV Trials)
5. **IMPAACT** (International Maternal Pediatric Adolescent AIDS Clinical Trials Group)
6. **MTN** (Microbicide Trials Network)


Bold = Prevention

HPTN Community Involvement Structure


GOAL: Advocate, Empower, Take Action, Build Capacity, Provide Technical Assistance



HVTN Community Involvement Structure



IMPAACT Community Participation




Source: François-Xavier Bagnoud Center at the University of Medicine and Dentistry of New Jersey (UMDNJ)

Community Partners

- To provide effective representation of and timely communication among the many communities, domestically and internationally, within which the DAIDS-sponsored Clinical Trials Networks conduct research.
- Responsibilities include enhancing intra- and inter-Network community input at all levels, identifying and developing programs to meet the training and support requirements of local Community Advisory Boards, increasing the representation and participation of community representatives from resource-limited settings, and identifying and addressing challenges to participation in clinical trials, such as economic, cultural, language, and beliefs.
- Membership will be drawn from the Network Community Advisory Boards, and representatives from DAIDS and the Managing Partners. Additional members will be appointed by the Director of DAIDS as necessary to ensure effective regional and national representation and effective communications. Logistic support, including operations and support for the Community Partners will be provided directly to the Community Partners by a DAIDS support contract.

Community Partners

DRAFT



Developing Good Participatory Practice Guidelines in HIV Prevention Trials

- UNAIDS Secretariat assisted by the AIDS Vaccine Advocacy Coalition convened a meeting on 27-28 September 2006 in London UK to initiate the process of developing Good Participatory Practice Guidelines in HIV Prevention Trials.
- Participants were 16 persons from research advocacy groups, research networks, research sponsors and activist non-governmental organisations (representing Africa, Latin America and Asia), the World Health Organization, and UNAIDS.

GPP Review Process

